More Post from the Author
- UMD Smith Student-Led Team Produces AI Platform to Transform Job Interview Prep
- Qiming Venture Partners Donates HK$3 Million to Tai Po Wang Fuk Court Aid Fund for Post-Fire Recovery
- MongoDB, Inc. to Present at the UBS Global Technology and AI Conference, the 53rd Annual Nasdaq Investor Conference, and Barclays 23rd Annual Global Technology Conference
- Vision Marine Technologies Reports FY 2025 Results and Highlights Strategic Expansion Following Nautical Ventures Acquisition
- ALLUONE Launches Customized Solution as the Plant-Care Market Continues to Grow
Indivior Statement RE: Delayed FDA Approval of SUBLOCADE Label Changes
Published on Wed 12 Feb 2025 8:07:04 UTC
RICHMOND, Va., Feb. 12, 2025 /PRNewswire/ --Indivior PLC (Nasdaq/LSE: INDV)provides the following update regarding its PDUFA action date for label changes (rapid initiation protocol and alternative injection sites) for SUBLOCADE (buprenorphine extended-release) Injection, which was scheduled for February 7, 2025:
Yesterday, February 11th, the FDA informed Indivior that, following acceptance of the proposed label for SUBLOCADE, there were no outstanding items to address, but that final review of the SUBLOCADE label changes has been delayed.
Indivior will provide further updates on the status of the approval of the proposed SUBLOCADE label changes as appropriate.
SOURCE Indivior PLC
More Post from the Author
- UMD Smith Student-Led Team Produces AI Platform to Transform Job Interview Prep
- Qiming Venture Partners Donates HK$3 Million to Tai Po Wang Fuk Court Aid Fund for Post-Fire Recovery
- MongoDB, Inc. to Present at the UBS Global Technology and AI Conference, the 53rd Annual Nasdaq Investor Conference, and Barclays 23rd Annual Global Technology Conference
- Vision Marine Technologies Reports FY 2025 Results and Highlights Strategic Expansion Following Nautical Ventures Acquisition
- ALLUONE Launches Customized Solution as the Plant-Care Market Continues to Grow